Therapeutics Acquisition Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RACA research report →
Price Chart
About the company
Therapeutics Acquisition Corp. , which operates as Research Alliance Corp. I, was founded in 2020 and is headquartered in Boston, Massachusetts.
- CEO
- Peter Kolchinsky
- IPO
- 2020
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on RACA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.09B
- P/E
- 0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.00
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 0.00%
- ROIC
- 0.00%
Latest fiscal year · YoY change
- Revenue
- +0.0%
- Gross Profit
- +0.0%
- Net Income
- +0.0%
- EPS
- +0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $18.08
- 52W Low
- $9.81
- 50D MA
- $10.24
- 200D MA
- $11.99
- Beta
- 0.00
- RSI (14)
- 55
- Avg Volume
- 137.58K
No earnings-call transcripts are available for RACA yet.
- Free Float
- 71.2%
- Shares Outstanding
- 105.64M
- Float Shares
- 75.23M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 29, 21 | Kolchinsky Peter | other | 209,100 |
| Jun 29, 21 | RA CAPITAL MANAGEMENT, L.P. | buy | 209,100 |
| Jun 24, 21 | Kolchinsky Peter | other | 889,218 |
| Jun 23, 21 | RA CAPITAL MANAGEMENT, L.P. | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RACA coverage
Recent articles, reports, and earnings notes.
No research on RACA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RACA report →Amalgamated Bank Has $425,000 Stock Holdings in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)
https://www.defenseworld.net · May 20
Q2 2024 EPS Estimates for TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Decreased by Analyst
https://www.defenseworld.net · May 20
POINT Biopharma Debuts as Publicly Traded Next-Generation Radiotherapeutics Company
globenewswire.com · Jun 30
Research Alliance Corp. I Announces Effectiveness of Registration Statement for Proposed Business Combination with POINT
businesswire.com · Jun 9
POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC
businesswire.com · Jun 4
POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC
globenewswire.com · Jun 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.